Columbia SOM
The Tabas Laboratory
PublicationsLab MembersContact UsSelected Laboratory Protocols

The Tabas laboratory studies the cellular biology of cardiometabolic disease, with an emphasis on the molecular-cellular mechanisms of advanced atherosclerosis and hepatic insulin resistance and NASH in obesity, and the links between these processes

The studies on advanced atherosclerosis have focused on integrated processes that combine to promote advanced plaque progression, with the current focus on defective clearance of the apoptotic cells (efferocytosis) and impaired inflammation resolution. In the efferocytosis field, we study (a) a macrophage receptor called MerTK; and (b) a process called high-burden efferocytosis, whereby a macrophage ingests and degrades multiple apoptotic cells over a short time period, requiring reprogramming of vesicular trafficking pathways and metabolism of molecules from degraded apoptotic cells. The inflammation resolution project investigates cellular mechanisms of the resolution process and its therapeutic potential, e.g., through the use of atherosclerosis-targeted nanoparticles packaged with resolution mediators. An exciting new area in the lab involves identifying specific mechanistic links between impaired resolution pathways and clonal hematopoiesis of indeterminate potential (CHIP), which is a major risk factor for atherosclerosis and coronary artery disease in humans over the age of 60.

The lab's studies on hepatic insulin resistance, which is an important driver of atherosclerosis, led to the discovery of a new calcium-stimulated pathway in hepatocytes that plays a key role in glucagon-mediated excessive glucose production, insulin resistance, fatty liver, dyslipidemia, impaired thrombolysis, and adipose tissue inflammation in the setting of obesity and type 2 diabetes. Ongoing studies are investigating: (a) the detailed molecular mechanisms involved in this new pathway; (b) how the pathway may promote atherosclerotic plaque progression by affecting plaque macrophages; and (c) strategies to translate our discoveries into new types of drugs to treat type 2 diabetes and prevent diabetes-driven atherosclerotic plaque progression.

Related to the lab's metabolism work, we study hepatocyte pathways in non-alcoholic steatohepatitis (NASH), with current investigations focused on (a) the role of a transcription factor called TAZ in both NASH fibrosis and NASH-associated hepatocellular carcinoma; (b) new mechanistic insight into known human genetic risk factors for NASH fibrosis, with current focus on MERTK and PNPLA3; and (c) new therapeutic strategies to prevent steatosis-to-NASH progression based on our findings.

Related to the lab's metabolism work, we study hepatocyte pathways in non-alcoholic steatohepatitis (NASH), with current investigations focused on (a) the role of a transcription factor called TAZ in both NASH fibrosis and NASH-associated hepatocellular carcinoma; (b) new mechanistic insight into known human genetic risk factors for NASH fibrosis, with current focus on MERTK and PNPLA3; and (c) new therapeutic strategies to prevent steatosis-to-NASH progression based on our findings.

The overall approach of the laboratory is to elucidate in-depth mechanisms using molecular-cell biological approaches; test causation in normal physiology and disease models using genetically engineered mice; probe relevance to humans through the study of normal and diseased human tissues and human genetics; and conceive and test novel and mechanism-based therapies in the cardiometabolic arena. In collaboration with the CUMC Cardiovascular and Metabolic Precision Medicine Program, led by Dr. Muredach Reilly, an important new, emerging direction in the lab is to apply our mechanistic insights related to advanced plaque progression and cardiometabolic disease to human genetics and studies with human iPSC-derived macrophages that can be genetically engineered using CRISPR/Cas9 to mimic or "correct" disease-causing human mutations.

The laboratory's philosophy is one of collaboration, not competition, and emphasis is placed on long-term, in-depth, and rigorous studies. Dr. Tabas places great emphasis on mentoring, particularly fostering independence, and career guidance. His trainees have had great success in career development grants from the NIH (K99/R00) and American Heart Association and subsequently with NIH R01 grants soon after leaving the lab for independent tenure-track Assistant Professorships at major university research organizations.

Postdoctoral Research Position:
The Tabas laboratory (http://www.tabaslab.com) in the Department of Medicine of Columbia University Medical Center is seeking a talented postdoctoral research scientist to study molecular-cellular pathophysiology of cardiometabolic disease, including atherosclerosis and obesity/insulin resistance.  The lab is looking to expand into new areas related to bioinformatic genetic analysis of macrophages and hepatocytes, including various new methods related to single cell sequencing, and into human genetics, including analysis of gene mutations related to new pathways discovered in the lab.

This is a highly competitive position, and only those candidates with the following qualifications will be considered: a Ph.D. or M.D/Ph.D. degree with (1) notable pre-doctoral accomplishments, especially high-quality publications in first-rate journals; (2) comprehensive experience in molecular and/or human genetics and bioinformatics; (3) excellent communication skills, particularly ability to comprehend rapidly spoken English and to speak fluently in English; and (4) no more than 2 years post-PhD.

Interested candidates who meet these qualifications should send cover letter and CV to iat1@columbia.edu. Columbia University Medical Center is an Equal Opportunity/Affirmative Action Employer





Ira Tabas, MD, PhD

Richard J. Stock Professor and Vice-Chair of Research
Department of Medicine
Professor of Pathology & Cell Biology (in Physiology and Cellular Biophysics)
Columbia University Medical Center


Department of Medicine
Columbia University

630 West 168th Street
New York, NY 10032


Office: PH 8-East-105F
Laboratory: PH 9-405/406
Tel (office): 212-305-9430
Tel (lab): 212-305-5669
Fax: 212-305-4834
iat1@columbia.edu



What's New?

Press Release

Change in Mitochondria is Critical for Clearing Dead Cells.
September 21, 2017

SCIENCE
PODCAST


TABAS AND GLASS, 339 (6116): 166-172

January 11, 2013

Ira Tabas [of Columbia University’s Department of Medicine] reviews recent advances in anti-inflammatory therapies in treating and preventing chronic disease. “Inflammation, once it gets going, can lead to tissue destruction. So the very elements of inflammation that can destroy the invading organisms can also destroy host tissue. And when tissue gets damaged, it can lead to tissue disfunction, according to Dr. Tabas.


Copyright © 2018 Ira Tabas, MD, PhD. All Rights Reserved.